15 completed, 1 approved for marketing, 1 not yet recruiting, 1 terminated. 11 Phase 1, 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 10, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow brensocatib: new trials by email Literature Review of brensocatib trials Research Report on brensocatib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants Brensocatib, Midazolam - Healthy Volunteers | Phase 1 | Not yet recruiting | Insmed Incorporated | 26 | 2026-10-29 | 2026-10-05 |
| A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) Brensocatib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Insmed Incorporated | 214 | 2024-12-16 | 2026-06-29 |
| A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants Brensocatib Oral Solution, Brensocatib Oral Tablet - Healthy Participants | Phase 1 | Completed | Insmed Incorporated | 24 | 2024-04-30 | 2024-06-13 |
| A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants Brensocatib - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 20 | 2023-12-27 | 2024-01-22 |
| A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis Without Nasal Polyps | Phase 2 | Completed | Insmed Incorporated | 288 | 2023-10-30 | 2026-09-30 |
| A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants Brensocatib, Clarithromycin - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 22 | 2023-07-28 | 2023-12-11 |
| A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants Brensocatib, Rifampin, Esomeprazole - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 32 | 2023-05-10 | 2023-08-21 |
| A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment Brensocatib - Hepatic Impairment | Phase 1 | Completed | Insmed Incorporated | 30 | 2022-10-04 | 2023-07-19 |
| A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants Brensocatib, Moxifloxacin, Placebo - Healthy Volunteer | Phase 1 | Completed | Insmed Incorporated | 48 | 2022-04-27 | 2023-03-27 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis Brensocatib, Placebo - Cystic Fibrosis | Phase 2 | Completed | Insmed Incorporated | 29 | 2021-11-30 | 2026-03-12 |
| A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment Brensocatib - Renal Impairment | Phase 1 | Completed | Insmed Incorporated | 28 | 2021-07-20 | 2023-04-18 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 3 | Completed | Insmed Incorporated | 1767 | 2020-12-01 | 2025-12-16 |
| STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 Brensocatib, Placebo - Covid19 | Phase 3 | Completed | University of Dundee | 406 | 2020-06-05 | 2023-08-22 |
| A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants INS1007, Placebo - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 82 | 2019-01-09 | 2023-07-03 |
| Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis Brensocatib 10 mg, Brensocatib 25 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Insmed Incorporated | 256 | 2017-10-31 | 2023-03-27 |
| A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects AZD7986, Verapamil, Itraconazole - Healthy Subjects | Phase 1 | Completed | AstraZeneca | 15 | 2016-01-22 | 2018-02-23 |
| Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study AZD7986, oral solution, 1 to 50 mg/mL, Placebo, oral solution - Safety, Pharmacokinetics, Pharmacodynamics, Food Effect | Phase 1 | Completed | AstraZeneca | 89 | 2014-12-03 | 2018-12-11 |
| An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis Brensocatib - Non-Cystic Fibrosis Bronchiectasis | Approved for marketing | Insmed Incorporated | 2025-11-04 |
Bronchiectasis (1) · COVID-19 (1) · Cystic Fibrosis (1) · Hidradenitis Suppurativa (1) · Renal Insufficiency (1)
Insmed Incorporated (15) · AstraZeneca (2) · University of Dundee (1)
United States (13) · United Kingdom (5) · Australia (4) · Bulgaria (4) · Germany (4) · Poland (4) · Spain (4) · Belgium (3) · Canada (3) · Denmark (3) · France (3) · Italy (3) · Netherlands (3) · Argentina (2) · Greece (2)
Annelize Koch, Dr (1) · Annelize Koch, MBChB, FFPM (1) · Bengt Larsson (1) · Carlos Fernandez, MD (1) · James Chalmers (1)
PMID 32897034, PMID 35411669, PMID 35976570, PMID 37198686, PMID 37538173, PMID 39040578, PMID 39574348, PMID 39938076, PMID 40267423, PMID 40753522, PMID 41519018, PMID 41586857, PMID 42461571
2014 (1), 2017 (1)